In brief
Retatrutide is a single peptide acting on the GIP, GLP-1 and glucagon receptors. This trial enrolled 338 adults, just over half men, with a body-mass index of 30 or more, or 27 or more with a weight-related condition, and gave weekly retatrutide at maintenance doses of 1, 4, 8 or 12 milligrams, or placebo, for 48 weeks. At 24 weeks, the primary endpoint, weight had fallen 7.2 percent on 1 milligram, 12.9 percent on 4, 17.3 percent on 8 and 17.5 percent on 12, against 1.6 percent on placebo, and losses continued to 48 weeks; every participant on 12 milligrams lost at least 5 percent and 83 percent lost at least 15 percent. Gastrointestinal events were the most common adverse effects, dose-related and mostly mild to moderate, and were reduced by a lower starting dose. Heart rate rose with dose, peaking at 24 weeks. Funded by Eli Lilly.
Study design
Phase-2, double-blind, randomised, placebo-controlled trial, 338 adults with obesity, retatrutide at four maintenance doses or placebo weekly for 48 weeks.
What it does not show
A phase-2 trial of 48 weeks with no long-term safety data, sponsor-funded, in a pharmaceutical form under medical supervision. It is not an approved drug and the compound is still in phase-3 trials.
A clinical trial tests a pharmaceutical form of a compound, in a defined patient group, under medical supervision, with a defined endpoint. None of that transfers to a research-grade vial, and this page does not suggest it does.
Where this paper is cited
- Retatrutide — Phase 2, 338 adults with obesity: mean weight change of −24.2% at 48 weeks on 12 mg weekly, against −2.1% on placebo.
Other papers cited for Retatrutide
- Study in humans Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Rosenstock et al. (2023), Lancet
- Study in humans LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept Coskun et al. (2022), Cell Metab
Further reading
- Research library: every paper cited on this site, by compound and by study type.
- GLP-1 family comparison
- How to read a certificate of analysis
- Lyophilised peptide storage and stability
How this page was made: the citation was retrieved from PubMed by PMID and checked against the title on the product page; the summary was written from the paper's abstract and reports only what the abstract reports. Read the paper itself before relying on any figure here.